A number of the factors mentioned above, as well as their mammalian orthologs, are believed to act in several stages of membrane traffic. Ypt1p, the yeast ortholog of the small GTPase Rab1, acts in both ER-to-Golgi and intra-Golgi transport (Bacon et al., 1989; Jedd et al., † Howard Hughes Medical Institute Yale University 1995). Sec34p and Sec35p were originally identified as components required for traffic between the ER and the New Haven, Connecticut 06520 ‡ Department of Molecular Biology Golgi (Wuestehube et al., 1996). More recently, however, it has been noted that SEC34 is identical to GRD20, a National Institute of Bioscience and Human-Technology gene whose product localizes to and acts at the trans-Golgi (Spelbrink and Nothwehr, 1999). The closest mam-Tsukuba, Ibaraki 305 Japan malian ortholog of Uso1p is p115 (Sapperstein et al., 1996). p115 has been reported to have a role in tethering COPI, as well as COPII, vesicles to the Golgi (Sö nnichsen et al., 1998; Alvarez et al., 1999; Allan et al., 2000). Collec-Summary tively, these findings suggest the presence of stagespecific factors that may interact with or recruit multi-TRAPP is a conserved protein complex required early in the secretory pathway. Here, we report two forms of stage transport factors. We previously identified a multiprotein complex called TRAPP, TRAPP I and TRAPP II, that mediate different transport events. Using chemically pure TRAPP I and TRAPP that stably associates with the Golgi under conditions that block ER-to-Golgi traffic (Sacher et al., 1998, COPII vesicles, we have reconstituted vesicle targeting in vitro. The binding of COPII vesicles to TRAPP 2000; Barrowman et al., 2000)
Figure 1. TRAPP Subunits Are Found in Two Different Complexes
(A) Trs33p is found in two high-molecularweight fractions. A radiolabeled lysate was prepared from a strain containing Bet3p-myc as described before (Sacher et al., 1998; Sacher and Ferro-Novick, 2001 ). An aliquot of 200 ϫ 10 6 cpm was applied to a Superdex-200 gel filtration column and 25 fractions of 1 ml each were collected. Each fraction was immunoprecipitated with 2 l of anti-c-myc antibody and analyzed on a 13% SDS polyacrylamide gel. The fractionation of Trs33p is shown. Molecular weight standards are thyroglobulin (669 kDa), ferritin (440 kDa), catalase (230 kDa), bovine serum albumin (67 kDa), and chymotrypsinogen A (25 kDa). (B) Trs65p, Trs120p and Trs130p are only found in TRAPP II. Radiolabeled lysates were prepared from an untagged strain (lanes 1 and 4) and a Bet3p-myc tagged strain (lanes 2 and 3), fractionated by gel filtration, and immunoprecipitated as described in (A). Fractions 9 (lanes 1 and 2) and 13 (lanes 3 and 4) are shown. TRAPP subunits are indicated between lanes 2 and 3. The band marked by an asterisk represents a proteolytic breakdown product of Trs120p (see Sacher et al., 2000) . by fractionating a radiolabeled lysate prepared from the TRAPP II complex. This was in fact the case (Figure 2A,  compare lanes 1 and 2) , and therefore, we deduced that Bet3p-myc tagged strain, and an untagged strain as a TRAPP I is the active component in our assay. To directly control. Each fraction was precipitated with anti-c-myc address this, the reconstitution assay was performed antibody. As shown in Figure 1B , the material in fraction using fractions from gel-filtered lysates enriched in ei-9 contained all ten previously identified TRAPP subunits ther TRAPP I or TRAPP II. As expected, the fraction (compare lane 2 with untagged control in lane 1), while containing TRAPP I showed a dose-dependent increase fraction 13 contained seven of the ten subunits of TRAPP in the reconstitution of transport activity (Figure 2B , (lane 3) as well as contaminating bands that were also lanes 1 and 2), while TRAPP II showed no activity (lanes present in the untagged control (lane 4). Interestingly, 3 and 4). These results directly demonstrate that TRAPP the three subunits missing in fraction 13 (Trs65p, I, but not TRAPP II, is required for ER-Golgi traffic in Trs120p, and Trs130p) were the products of the genes vitro. that did not suppress bet3-1. The same result was obtained with other tagged subunits (data not shown).
A Temperature-Sensitive trs130 Mutant Accumulates While the subunits in fraction 9 were found in equimolar Aberrant Golgi Structures amounts, some of the subunits in fraction 13, notably
To address the role of TRAPP II in membrane traffic, we Trs85p and Trs20p, were clearly substoichiometric comconstructed a temperature-sensitive mutant in TRS130, pared to the other subunits ( Figure 1B, compare lanes a gene whose product is unique to TRAPP II. The trs130 2 and 3). We have named the smaller complex found in mutant was constructed by truncating the last 33 amino fraction 13 TRAPP I, and the larger complex found in acids of TRS130 with (trs130 ts1 ) or without (trs130 ts2 ) the fraction 9 TRAPP II. aid of a transposable element. The phenotype of both mutants was examined morphologically by electron microscopy (EM) and compared to other mutants. Mutants TRAPP I, but Not TRAPP II, Functions that block vesicle targeting between the ER and Golgi in ER-Golgi Transport In Vitro characteristically accumulate dilated ER as well as We previously reported that the depletion of Bet3p from small, ‫05ف‬ nm diameter vesicles. This morphology was fractions used in an in vitro transport assay, which meapreviously noted for bet3-1 (Rossi et al., 1995) , and sures ER-Golgi membrane traffic (Ruohola et al., 1988) , the same phenotype was observed for a mutant with a blocks the binding of vesicles to the Golgi. Reconstitudefect in another TRAPP subunit, bet5 (compare wildtion of transport was dependent upon the addition of type cells in Figure 3A to bet5-1 in Figure 3D ). The cytosol that contains Bet3p (Sacher et al. 1998 ; Barmorphology of trs130 ts2 ( Figure 3C ) and trs130 ts1 (data not rowman et al., 2000). In these earlier studies, the integrity shown) at 37ЊC was strikingly different from ER-Golgi of the complex was not assessed. When this experiment blocked mutants. Instead of dilated ER and small vesiwas performed, both TRAPP I and TRAPP II were found cles, an abundance of toroid-shaped structures accuto be unstable in the absence of Bet3p (data not shown). mulated, similar to the aberrant Golgi reported in mu-Since Bet3p is a component of both TRAPP I and tants such as sec7, sec14, sft1, and pik1, whose TRAPP II, we wanted to determine which complex was products act at the level of the Golgi (Novick et al., 1980 ; required for reconstitution. Cytosols used to reconsti-Banfield et al., 1995; Walch-Solimena and Novick, 1999). tute transport activity in vitro are prepared by centrifuga-
The morphology of the trs130 mutants was dependent on the temperature shift, as cells grown at the permis-tion of a yeast lysate at a speed that may pellet the larger After a 4 min pulse, CPY was found in the p1 form in wild type and the mutants ( Figure 4A, lanes 1, 3, 5 , 7, sive temperature (25ЊC) were phenotypically indistinand 9). Radiolabeled protein was converted to the maguishable from wild type (compare Figure 3B Proteolytic activation in the vacuole yields the mature proceeded past an initial block between the ER and Golgi and was then transported to the Golgi. form (Stevens et al., 1982) . Pulse-chase experiments were performed to examine the processing of CPY in To examine the processing of invertase, wild-type and mutant cells (sec18, bet3, trs130, and trs120) were radio-trs130, as well as wild type and mutants that block ERto-Golgi (bet3 and sec18) and intra-Golgi traffic (sft1). labeled at 37ЊC, and the internal and periplasmic forms into the periplasm (lane 11). In contrast, the secretion of invertase was defective in the trs130 mutant (lane 12), and incompletely glycosylated forms of the enzyme accumulated (lane 2) that were precipitated with anti-␣1→6 antibody (lane 7). The more highly glycosylated form was precipitated with anti-␣1→3 antibody (data not shown). The same result was obtained with a ts 
2000)
, the absence of this gene product, in a strain containing Bet3p-myc, resulted in a reduction in growth at 37ЊC and a block in ER-to-Golgi transport (Table 1) . of invertase were immunoprecipitated. Wild-type cells showed no accumulation of radiolabeled invertase (Fig-Our analysis of the trafficking of CPY and invertase in the bet3 mutant implied that Bet3p operates in more ure 4B, lane 1) but secreted a fully glycosylated form than one transport event. When we pulse-labeled bet3 at 25ЊC and then shifted the mutant to 37ЊC, a second block was revealed. An early Golgi form of CPY (presumably p1Ј), as well as some p2 CPY, appeared at 37ЊC and persisted for the duration of the chase ( Figure 4C ). Thus, Bet3p plays a role in both ER-to-Golgi traffic and traffic through or from the Golgi.
TRAPP I and TRAPP II Cofractionate on Sucrose Density Gradients
Previous work has shown that Trs130p (TRAPP II) and Trs33p (TRAPP I and TRAPP II) cofractionate with each other and Golgi, but not ER, marker proteins on sucrose velocity gradients (Barrowman et al., 2000). Since we propose that TRAPP II acts in Golgi transport and TRAPP I in ER-to-Golgi transport, we next addressed whether the two complexes localize to the same or different subcompartments of the Golgi. To determine the localization of TRAPP subunits on the Golgi, we fractionated yeast lysates on sucrose density gradients capable of resolving subcompartments of the Golgi. We followed the ER-Golgi SNARE Bet1p as a marker for early Golgi, as well as GDPase and Kex2p as markers for more distal Golgi compartments. Western blots of gradient fractions revealed that Trs130p fractionated in one peak with Bet1p ( Figure 5A 
TRAPP, the role of TRAPP I in vesicle tethering can now be addressed.
To begin these studies, we first tested if immobilized TRAPP can bind COPII transport vesicles formed in vitro.
of the vesicles to the beads showed a linear response over the range tested (not shown). We estimated that Initially, binding studies were performed with a mixture of both forms of the TRAPP complex (TRAPP I/II). TRAPP ‫%03-%01ف‬ of the vesicles in the reaction bound to the beads. The radiolabel precipitated on the TRAPP I/II I/II was immobilized by treating IgG-Sepharose beads with a lysate prepared from a strain in which Bet3p is beads represents pro-␣-factor contained within a membrane since pretreatment of the vesicle fraction with 1% fused to protein A (Sacher et al., 2000) . As a control, beads were treated with a lysate prepared from an iso-Triton X-100 abolished binding of radiolabel to the beads (Figure 6A , compare hatched bars in TRAPP I/II and genic untagged strain. Vesicles were formed in vitro by incubating donor permeabilized yeast cells, containing control data sets). Furthermore, binding of radiolabeled pro-␣-factor was dependent upon vesicle production as radiolabeled pro-␣-factor, with cytosol and ATP. Under these conditions vesicles, but not ER, are released from inhibition of vesicle formation with apyrase significantly reduced binding to background levels (Figure 6A , com-the cells (Groesch et al., 1990) . As shown in Figure 6A sec34-1, and sec35-1 ) that harbor lesions in the genes that encode the different tethering factors. Although and the washed beads were assayed for their ability to bind COPII vesicles in vitro. The results shown were fractions prepared from these mutants were defective for transport in vitro ( Figure 7A, top panel) , this defect normalized to the amount of Trs33p that bound to the beads. As a control, we also treated beads to a column was not at the level of TRAPP I-dependent tethering as vesicles produced from these mutants bound to TRAPP I fraction (fraction 23) that did not contain either TRAPP complex (see Figure 1A ). As shown in Figure 6B , vesicles as efficiently as wild type (Figure 7A, bottom panel) . Excess amounts of GDI, which inhibits Ypt1p activity by bound to TRAPP I, but binding to TRAPP II was the same as the control (see legend to Figure 6) . extracting the GDP-bound form of Ypt1p from membranes (Garrett and Novick, 1995) , also did not interfere TRAPP II may fail to bind to COPII vesicles in our studies because it lacks function when bound to IgG-with binding. Furthermore, when antibody to the vesicle SNARE Bos1p was added in amounts sufficient to block Sepharose beads. Previous studies have shown that TRAPP I is an exchange factor for Ypt1p (Wang et al., transport in vitro, COPII vesicle binding to TRAPP I was not affected (data not shown).
2000). Since Ypt1p acts in ER-Golgi and Golgi traffic, both TRAPP I and TRAPP II may exchange nucleotide
Previous studies have shown that Bet3p, a component of TRAPP I and TRAPP II, binds tightly to Golgi on Ypt1p. Beads containing the TRAPP I or TRAPP II complex were prepared as described above and as-membranes (Barrowman et al., 2000) . Golgi membranes, as well as COPII vesicles, are released from permeabil-sayed for their ability to stimulate the uptake of [ 35 S] GTP␥S onto Ypt1p. As shown in Figure 6C , when normal-ized yeast cells in the presence of cytosol and an ATPregenerating system (Ruohola et al., 1988) . Therefore, ized to the amount of Trs33p that bound to the beads, TRAPP I and TRAPP II had similar activities. These data the radioactivity we are monitoring in our binding studies could represent vesicles bound to Golgi, or labeled ␣ demonstrate that although TRAPP II is active on beads, it cannot recognize COPII vesicles. Furthermore, our factor that was delivered to the Golgi. The finding that TRAPP I, but not TRAPP II, binds membrane-bound ␣ findings indicate that both forms of TRAPP can exchange nucleotide on Ypt1p.
factor makes this seem unlikely. Nonetheless, to rule out this possibility, we formed COPII vesicles with purified COPII coat components as described before (Barlowe et al., 1994; Barlowe, 1997) . The protocol we employed yields vesicles that are free of cytosol and Golgi, elimi-If TRAPP I specifically recognizes and binds to COPII vesicles, the vesicle binding event we reconstituted in nating the possible artifacts described above. Furthermore, unlike the binding studies shown in Figure 6 , these vitro may not require other tethering factors. To address Fractions prepared from the ypt1-3, uso1-1, sec34-1, and sec35-1 mutants display defects in ER-to-Golgi traffic in vitro. Fractions were prepared as described before (Groesch et al., 1990) except cells were converted to spheroplasts during a 1 hr incubation at  25ЊC, regenerated at 25ЊC for 90 min, and assayed at 25ЊC. Results are expressed as percentage of wild- prepared from either wild type, ypt1-3, uso1-1, sec34-1, or sec35-1.  (B) Chemically pure TRAPP I binds COPII vesicles. TRAPP I was purified as described in the Experimental Procedures. COPII vesicles were produced from purified COPII components as described before (Barlowe et al., 1994; Barlowe, 1997) . Increasing amounts (10, 20, and 40 l) of beads containing TRAPP I or 40 l of empty beads (control) was incubated with vesicles produced in the presence of ATP. Empty beads (0-30 l) were added to samples so that all reactions contained 40 l of beads. Approximately equal amounts of ConA precipitable counts (a measure of vesicles) were used in all the binding assays, including those containing GTP␥S. For the GTP␥S budding reaction, GTP␥S at 100 M was used in place of GTP. A silver-stained gel showing purified TRAPP I (lane 2) is shown to the right of the graph. The bands marked with an asterisk were not contaminants of the preparation as they were also seen in lane 1, which only contained sample buffer. The minor TRAPP I component, Trs85p (see Figure 1B, lane 3) , was not revealed with silver stain but could be detected by Western blot analysis using the ECL method (not shown). experiments were performed with chemically pure COPII coat, an increase in binding should be observed in the presence of GTP␥S, a nonhydrolyzable analog of TRAPP I that was immobilized on calmodulin agarose beads (see Figure 7B ), and purified as described in the GTP that is known to stabilize the COPII coat (Barlowe  et al., 1994) . Instead, binding was drastically reduced Experimental Procedures from a strain in which Trs33p was TAP tagged. Western blot analysis revealed that ( Figure 7B ), suggesting that COPII vesicles must uncoat before TRAPP I can bind. purified TRAPP I did not contain any TRAPP II-specific contaminants (not shown).
The Binding of TRAPP I to COPII Vesicles Is Specific and Does Not Require Other Tethering Factors

type transport. Bottom panel: TRAPP I binds to COPII vesicles in the absence of other tethering factors. Vesicle budding reactions were performed with donor cells and cytosol
To determine whether other types of vesicles bind to TRAPP I, chemically pure TRAPP I was incubated with Using this highly purified system, COPII vesicles bound to TRAPP I in a concentration-dependent manner a 10,000 ϫ g supernatant prepared from a sec6-4 mutant grown at 25ЊC and then shifted for 1 hr at 37ЊC, to ( Figure 7B ). We estimated that at the highest concentration of TRAPP I used in these studies, ‫%03-%52ف‬ of accumulate post-Golgi vesicles (Walworth and Novick, 1987) . Snc1p, the post-Golgi vesicle SNARE, accumu-the vesicles bound to the beads. As these binding studies were performed in the absence of cytosol, we lated intracellularly under these conditions (Figure 7C,  compare lane 3 with lane 4) . The membranes that accu-can conclude that cytosol is not required for TRAPP I-dependent vesicle binding. Consistent with this conclu-mulated were sealed, since a 4.5-fold increase in invertase activity was found upon the addition of Triton sion, we have found that the addition of cytosol to cytosol-free vesicles does not increase their efficiency of X-100. Prior to the shift, Snc1p was also found on membranes (lane 3). Previous studies have shown that these binding (not shown). If TRAPP I interacts directly with the membranes include the plasma membrane, endosomes, observed thus far (Jiang et al., 1995;  our unpublished data). and Golgi (Protopopov et al., 1993; Lewis et al., 2000) .
Recent work has implicated large protein complexes As shown in Figure 7C Guo et al., 1999) , it is functionally linked the ten previously identified subunits. This complex is to the other Exocyst components and all members of required for membrane traffic between the ER and Golgi this complex act at the same stage of the secretory in vitro. Consistent with this role, we find that mutants pathway. Our results showing that TRAPP I binds to with defects in TRAPP I subunits block the transport of COPII, but not post-Golgi, vesicles is important since it CPY in a pre-Golgi compartment. The larger complex, clearly demonstrates that one of these putative tethering TRAPP II, contains all ten of the previously identified complexes binds to a specific class of vesicles. TRAPP subunits in equimolar amounts (Sacher et al., The interaction of a transport vesicle with its target 1998, 2000). Fractionation of lysates containing either membrane is a multistage process that involves recogni-Trs65p-myc, Trs120p-myc, or Trs130p-myc indicated tion followed by one or more tethering events. The bindthat these subunits were found exclusively in TRAPP II, ing of a COPII vesicle to TRAPP I may be the first of and no other pool was detected (M. S. and S. F.-N., these events, implicating TRAPP I as the tether that is unpublished data). Genetic, biochemical, and morphomost likely to confer specificity. Consistent with this logical analysis of the trs130 mutant indicates that proposal, we see specificity in our binding assay. We TRAPP II functions in Golgi traffic or in exit from the propose that TRAPP I binds to an uncoated ER-derived Golgi.
vesicle through an unidentified ligand. Since the known That the different forms of TRAPP mediate different tethering factors are not needed for the binding of transport events and interact differentially with COPII TRAPP I to vesicles, this ligand does not appear to be vesicles suggests that TRAPP I is a stage-specific teth-Ypt1p, Uso1p, or the Sec34p/Sec35p complex. Once ering factor. TRAPP I binds COPII vesicles, but not post-TRAPP I binds to the vesicle, it activates Ypt1p, con-Golgi vesicles and other membranes (endosomes, verting it from its GDP-bound form to its GTP-bound plasma membrane, Golgi). It is unlikely that TRAPP I form. The activation of Ypt1p by TRAPP I may be the recognizes the COPII coat on these vesicles because signal that the vesicle has reached its correct acceptor COPII coat components do not bind to TRAPP I under compartment. This then leads to the recruitment of other conditions where Ypt1p binds (M. S. and S. F.-N., unpubtethers, as the binding of COPII vesicles to TRAPP I may lished data). Furthermore, the observation that GTP␥S be reversible in vivo in their absence. Consistent with blocks vesicle binding in vitro suggests that COPII vesithis hypothesis is the recent finding that p115, the mamcles must uncoat before they bind to TRAPP I. Like the malian ortholog of Uso1p, is recruited to membranes by TRAPP complexes, the small GTP binding protein Ypt1p activated Rab1 (Allan et al., 2000) . The binding of Uso1p acts in both ER-to-Golgi and Golgi traffic. Our finding to membranes has also been shown to be dependent on that Ypt1p is activated by two distinct but related ex-Ypt1p (Cao et al., 1998) , and Uso1p-dependent vesicle change factors (TRAPP I and TRAPP II) explains how tethering requires the Sec34/Sec35p complex in vitro this small GTP binding protein can act in two different (VanRheenen et al., 1998, 1999) . These late tethering transport events. This result also implies that the binding events may be a prerequisite to SNARE pairing (Allan of each TRAPP complex to vesicles occurs via a stageet al., 2000), the final step in docking a COPII vesicle to specific receptor and not Ypt1p.
the Golgi. Based on the findings reported here and the pheno-Since TRAPP I resides in the cytosol and on memtype of the trs130 mutant, a possible role for TRAPP II branes (Sacher et al., 1998) , an alternate proposal is is to bind retrograde vesicles in the Golgi. Such vesicles that cytosolic TRAPP I may bind to COPII vesicles. The would arise from a later Golgi compartment and bind to activation of Ypt1p may then enable TRAPP I to bind to early Golgi. In this respect, it is interesting to note that we its receptor on the Golgi, where other tethering factors have found that trs130 ts2 displays synthetic interactions are recruited. A third possiblity is that TRAPP I acts with ret2-1 (a mutant with a defect in a COPI subunit) solely to activate Ypt1p, which, in combination with and arf1⌬ (a mutant that lacks Arf1p that is required for other tethering factors, allows the vesicle to bind to the COPI vesicle formation), but not with sec13-1, sec23-1, Golgi. This can be ruled out as genetic studies have sec24-1, and sec31-1 (mutants defective in COPII subshown that the complete loss of Ypt1p and the other units). Alternatively, TRAPP II may play a role in exit tethers can be bypassed, while the complete loss of from the Golgi. Golgi-to-endosome/vacuole trafficking TRAPP cannot (Sapperstein et al., 1996; VanRheenen  is unlikely, since the trs120 and trs130 mutants do not  et al., 1998, 1999; Barrowman et al., 2000) . accumulate endosomal-like structures, and defects in Using an in vitro vesicle binding assay that employs COPII vesicles and chemically pure TRAPP I, we have traffic on the endocytic/vacuolar pathway have not been To accumulate post-Golgi vesicles in the sec6-4 mutant, NY 17 described a role for TRAPP I in vesicle tethering. Since (MATa ura3-52 sec6-4) was incubated for 1 hr at 37ЊC and a 10,000 ϫ the ligand on the ER-derived vesicle that recognizes g supernatant was prepared as described before (Walworth and TRAPP I is not one of the known tethering factors, a Novick, 1987) , except 75 units of cells at OD 599 ϭ 1 were lysed in challenge for the future will be to identify this factor 1.1 ml of lysis buffer. Binding reactions were performed with 75 l through the use of biochemical and genetic approaches. of lysate and 10 l of an IgG-Sepharose bead slurry as described above. The vesicles and other Snc1p-containing membranes were followed by Western blot analysis using antibody to the SNARE Experimental Procedures  Snc1p (1:1000 dilution) . To obtain chemically pure TRAPP I, Trs33p was tagged with the In Vitro Reconstitution Experiments TAP tag and purified as described before (Rigaut et al., 1999) with The in vitro transport assay and the preparation of the fractions were the following minor modifications. Cells were lysed in buffer conperformed as described previously (Ruohola et al., 1988; Groesch et  taining 20 mM HEPES (pH 7.2), 150 mM NaCl, and the salt concentraal., 1990; Lian and Ferro-Novick, 1993; Sacher et al., 1998) . For the tion was adjusted to 300 mM prior to centrifugation. The lysate (1.3 reconstitution experiments, lysates were prepared from SFNY 26-3a g) was centrifuged at 170,000 ϫ g for 4 hr to pellet TRAPP II before (MATa ura3-52) or SFNY 904 . A total of 1050 it was incubated with IgG-Sepharose beads. To release TRAPP from units of cells at OD 600 ϭ 1 were converted to spheroplasts as dethe beads, 350 U of TEV Protease were used and the incubation scribed before (Sacher and Ferro-Novick, 2001 ) and lysed in 2.5 ml was performed at room temperature for 2 hr. Binding reactions were of 20 mM HEPES (pH 7.2) by pipetting and gently vortexing the performed in buffer B88 (Barlowe, 1997) containing 2 mM CaCl 2 . solution. After cell lysis, 10ϫ concentrated Transport Assay buffer Western blot analysis of the purified TRAPP I complex, using the was added to the lysate to give a final composition of 25 mM HEPES ECL method, confirmed that it was devoid of Trs130p, a TRAPP (pH 7.2), 115 mM potassium acetate, 2.5 mM magnesium acetate.
II-specific component. The lysates were centrifuged at 100,000 ϫ g for 1 hr, and aliquots (300-500 l) containing 5 mg of protein were then passed over a
